Trial of Vaccine Therapy in Recurrent Platinum Sensitive Ovarian Cancer Patients

Exclusion Criteria

• •Eligible to otherwise curative treatment.
• •History of prior malignancy, other than ovarian cancer, within the last 5 years, with the exception of curatively treated basal cell carcinoma and cancer in situ cervix uteri.
• •Prior surgery within the past 28 days
• •Clinical ascites or metastatic pleural fluid
• •Active infection requiring antibiotic therapy.
• •Have known active central nervous system (CNS) or leptomeningeal metastasis (brain metastasis). Patients with signs or symptoms of neurological compromise should have appropriate radiographic imaging performed before study entry to rule out brain metastasis.
• •Significant cardiac or other medical or mental illness that would limit activity or survival, such as severe congestive heart failure, unstable angina, serious cardiac arrhythmia or psychosis.
• •Pregnancy or lactation
• •Previous adverse reactions to vaccines such as asthma, anaphylaxis or other serious reactions.
• •History of immunodeficiency or autoimmune disease such as but not limited to rheumatoid arthritis, systemic lupus erythematosus, scleroderma, polymyositis-dermatomyositis, juvenile onset insulin dependent diabetes, or a vasculitic syndrome.
• •Positive for syphilis (treponema pallidum), HIV, Hepatitis B and C tests
• •Use of systemic glucocorticoids.
• •Prior anti-cancer treatment, including radiotherapy, chemotherapy immunotherapy and/or immunomodulating agents stopped for less than 4 weeks before first study treatment administration. Anti hormonal treatment, such as Tamoxifen, may continue until first study treatment administration.
• •Any reason why, in the opinion of the investigator, the patient should not participate.